Evidence map›Paper›PMID 29983902›Full record

ArticleOncology reviews2018

The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review.

Michael Roche, Laura Parisi, Linda Li, Amy Knehans, Rebecca Phaeton, Joshua P Kesterson

Open access · goldAbstract readScoping Review
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology reviews, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Michael RocheDepartment of Obstetrics and Gynecology, Penn State Hershey Medical Center, Hershey, Pennsylvania.
Laura ParisiDepartment of Obstetrics and Gynecology, The University of Kansas Medical Center, Kansas City, Kansas.
Linda LiDepartment of Obstetrics and Gynecology, Penn State Hershey Medical Center, Hershey, Pennsylvania.
Amy KnehansHarrell Health Sciences Library, Penn State College of Medicine, Hershey, Pennsylvania.
Rebecca PhaetonDivision of Gynecologic Oncology, Penn State Hershey Medical Center, Hershey, Pennsylvania, USA.
Joshua P KestersonDivision of Gynecologic Oncology, Penn State Hershey Medical Center, Hershey, Pennsylvania, USA.
Penn State Milton S. Hershey Medical Center · USUniversity of Kansas Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer is the leading cause of mortality among gynecologic malignancies, with most cases diagnosed at an advanced stage. Despite an initial response, most develop a recurrence and subsequent resistance to standard therapies. Pemetrexed (Alimta

Indexed as

Alimtafallopian tube cancerPemetrexedprimary peritoneal cancerrecurrent epithelial ovarian cancer

Identifiers

PMID29983902
PMCPMC6007165
OpenAlexW2791088496

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.